Researchers at RUSH are leading efforts to cure disease and promote health equity — in Chicago and around the world. Our students and faculty work together on the frontiers of clinical, basic science and community-based research, in order to improve care for patients at RUSH and beyond.
Scientists have uncovered a new understanding of how COVID-19 causes severe multi-organ injury in some patients and the pathways to stopping the cytokine storms behind them, according to new research published in the Journal of Clinical Investigation Insight.
The FDA-approved, lipid-lowering medication gemfibrozil may prevent the progression of this devastating neurodegenerative disease, according a RUSH study in the Journal of Neuroscience. Read more
The notorious spike protein of SARS-CoV-2 reduced lung tumors in laboratory studies, raising the possibility that the virus might also yield a treatment for lung and other cancers. Read more
New research published in Neurology continues a legacy of work examining the association between Alzheimer’s dementia and flavonoids. The study suggests dietary intake of flavonols may be associated with slower decline in cognitive abilities. Read more
